297 related articles for article (PubMed ID: 35225058)
1. PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.
Alhesa A; Awad H; Bloukh S; Al-Balas M; El-Sadoni M; Qattan D; Azab B; Saleh T
Int J Immunopathol Pharmacol; 2022; 36():3946320221078433. PubMed ID: 35225058
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
[No Abstract] [Full Text] [Related]
3. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
Huang X; Anderson SA; Siegal GP; Wei S; Liu S; Yang J; Roisin P; Pickens JT; Huo L; Sahin AA; Granada CP; Chen S
Clin Breast Cancer; 2024 Jun; 24(4):e310-e318. PubMed ID: 38492995
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
9. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
[TBL] [Abstract][Full Text] [Related]
13. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
14. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
15. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S; Kawakami H; Shiraishi O; Kanemura H; Suzuki S; Haratani K; Hayashi H; Yonesaka K; Chiba Y; Yasuda T; Nakagawa K
Esophagus; 2023 Apr; 20(2):281-289. PubMed ID: 36484900
[TBL] [Abstract][Full Text] [Related]
16. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Yeong J; Lum HYJ; Teo CB; Tan BKJ; Chan YH; Tay RYK; Choo JR; Jeyasekharan AD; Miow QH; Loo LH; Yong WP; Sundar R
Gastric Cancer; 2022 Jul; 25(4):741-750. PubMed ID: 35661944
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
18. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
